
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Watson Pharmaceuticals Inc. and Debiopharm S.A. have agreed to market triptorelin pamoate (Trelstar Depot, 3.75 mg, and Trelstar LA, 11.25 mg) within the United States and Canada.





